Prospective Study to Evaluate the Safety of a 4-month Treatment With Depigoid Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml) in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Mild Persistent or Intermittent Asthma.

Trial Profile

Prospective Study to Evaluate the Safety of a 4-month Treatment With Depigoid Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml) in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Mild Persistent or Intermittent Asthma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs House dust mite allergy immunotherapy Laboratorios LETI (Primary)
  • Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2012 Status changed from suspended to discontinued as reported by European Clinical Trials Database.
    • 14 Jul 2012 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
    • 26 May 2012 Actual initiation date (17 Feb 2012) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top